T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects
children, is still a medical challenge, especially for refractory patients for whom therapeutic …

The CD99 gene encodes a transmembrane protein that is involved in cell differentiation,
adhesion, migration, and protein trafficking. CD99 is differentially expressed on the surface …

T‐lineage acute lymphoblastic leukemia (T‐ALL) accounts for about 15% of pediatric and
about 25% of adult ALL cases. Minimal/measurable residual disease (MRD) assessed by …

Central nervous system (CNS) relapse is a significant cause of treatment failure among
patients with acute lymphoblastic leukemia. In prior work we found that the meninges, the …

The CD99 antigen is a transmembrane protein expressed in a broad variety of tissues,
particularly in hematopoietic cells, thymus, endothelial cells, etc. It participates in several …

Leukemia is a group of hematologic cancers distinguished by the proliferation of abnormal
lymphoid cells in the bone marrow. Based on rate of progression, leukemia can be classified …

T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult
haematologic disease still associated with an unsatisfactory cure rate. Unlike B-ALL, the …

Our study aimed to determine the expression pattern and clinical relevance of CD 99 in
paediatric B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL). Our findings …

Clofarabine, an FDA approved purine analog, is used in the treatment of relapsed or
refractory acute lymphoblastic leukemia. Clofarabine acts by inhibiting DNA synthesis. We …

Chimeric antigen receptor (CAR T) therapy produced excellent activity in patients with
relapsed/refractory B-lineage malignancies. However, extending these therapies to T cell …